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ABSTRACT 
Coronavirus pandemic or COVID-19 is a global public health emergency at this period. Presently, no pharmacological treatment is known to treat 
this condition. Hydroxychloroquine (HCQ), a derivative of chloroquine (CQ), was first synthesized in 1946 by adding a hydroxyl group to CQ, which 
is much less toxic than CQ in animal studies. Other than being an anti-malarial drug, it was revealed to have various pharmacological effects and one 
of those is its anti-viral property. CQ, as well as HCQ, has been used in SARS (Severe Acute Respiratory Syndrome) coronavirus infection due to its 
antiviral properties. Even though various scientists have considered HCQ as a better therapeutic approach than CQ for the treatment of coronavirus 
infection, there are various adverse drug reactions associated with HCQ treatment in COVID-19 patients. In this paper, we review the anti-viral 
mechanism, various adverse drug reactions, and side effects of HCQ for COVID-19 treatment. 
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INTRODUCTION 
Hydroxychloroquine (HCQ) goes to the group of antimalarial agents, but 
the gratitude of its assistance in various diseases other than malaria 
dates back to 1894 when Payne stated that quinine was effective in 
cutaneous lupus [1]. Chloroquine (CQ) and HCQ were revealed to have 
many immunomodulatory effects and have a conventional role in the 
administration of rheumatic infections, such as rheumatoid arthritis and 
systemic lupus erythematosus, skin diseases and in the management of 
chronic fever. Later, other metabolic, cardiovascular, antithrombotic, and 
antineoplastic effects of HCQ were shown. Wallace et al. found that HCQ 
was also revealed to have a promising result on lipid profiles in patients 
with rheumatic diseases [2].  
Its additional beneficial effects were also shown periodically in other 
diseases. It was shown to be very effective in KFD i.e. Kikuchi-
Fujimoto disease, a benevolent disease categorized by 
lymphadenopathy, fever, and leukopenia usually happens in young 
women [3, 4]. Sarcoidosis induced skeletal and metabolic effects 
were effectively cured with HCQ in patients usually who were not 
candidates for glucocorticoid treatment. It also enabled steroid 
discontinuation in patients with subglottic stenosis [5-7]. 
Besides, HCQ was found to be active against bacterial as well as viral 
infections. In 2002-2003, an immediate pandemic of severe critical 
respiratory syndrome was caused due to Human coronavirus 
(hCoV). To date, no particular antiviral drugs are existing for the 
inhibition or management of hCoV infection. In vitro studies showed 
that CQ inhibits the repetition and spread of coronavirus and stops 
infection with hCoV in neonatal mice [8-10].  
Presently, an epidemic of cases through unexplainable low respiratory 
infections detected in the major urban area in China's Hubei province i.e. 
Wuhan, was first informed to the WHO Republic Office in China on 
December 31, 2019. At first, the causative agent was unidentifiable and 
these primary cases were characterized as "pneumonia of unknown 
etiology." The root of this disease is now recognized as an innovative 
virus belonging to the coronavirus (CoV) family. 
On February 11, 2020, the disease caused by this new CoV was 
announced as "COVID-19," i.e. "coronavirus disease 2019" by WHO 
Director-General, Dr. Tedros Adhanom Ghebreyesus [11]. This new 
virus appears to be extremely contagious and has rapidly spread all 
over the world. As on 1st March 2020, a total of 7,169 confirmed 
cases of COVID-19 had been reported globally, while on June 17, 
2020, 13,616,593 confirmed cases along with 585,727 deaths had 
been reported globally, of which 1,003,832 cases and 25,602 deaths 
were in India, according to WHO [WHO Situation Report 179]. The 
number of COVID-19 cases is still on the rise.  
There is no precise antiviral treatment suggested for COVID-19, and no 
vaccine is presently available. The treatment is symptomatic, and oxygen 
therapy signifies the major treatment involvement for patients with a 
major infection. Automated ventilation may be compulsory in cases of 
respiratory failure refractory to oxygen therapy; however, hemodynamic 
support is important for handling septic shock.  
Though no antiviral treatments have been accepted, numerous 
methodologies have been suggested, such as lopinavir/ritonavir 
(400/100 mg every 12 h), chloroquine (500 mg every 12 h), alpha-
interferon (e. g., 5 million units by aerosol inhalation twice per day) 
and HCQ (200 mg every 12 h). As of 23rd February 2020, seven 
clinical trial registries have been found in the Chinese Clinical Trial 
Registry for using HCQ to COVID-19 treatment. It has been described 
that the safe dosage of HCQ (6–6.5 mg/kg per day) could reach 
serum levels of 1.4–1.5 μM in humans [12]. 
The statement from the National Task Force for COVID-19 of the 
Indian Council of Medical Research (ICMR) dated March 21, 2020, 
commends the use of HCQ for prophylaxis in  
(i) Asymptomatic healthcare workers tangled in the care of 
suspected and confirmed patients, and 
(ii) Household contacts of confirmed patients with viral infection [13]. 
HCQ: chemistry and pharmacokinetics 
 
 
Fig. 1: Structure of HCQ  
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HCQ belongs to a class of drugs known as 4-aminoquinolines [14]. It is 
absorbed rapidly and entirely after oral administration, partly protein-
bound in plasma, and moderately metabolized in the liver via the 
cytochrome P450 (CYP) enzymes. HCQ is metabolized to one major 
metabolite, N-desethylhydroxychloroquine, by CYP enzymes CYP2D6, 
CYP2C8, CYP3A4, and CYP3A5 through the N-desethylation pathway. A 
relation has been shown between blood N-desethylhydroxychloroquine 
levels and the effectiveness of treatment with HCQ [15]. 
HCQ: anti-viral mechanism of action 
HCQ is generally considered immunomodulatory instead of 
immunosuppressant. It can restrict by the glycosylation of ACE2 
(angiotensin-converting enzyme 2) then decrease the binding 
efficacy among ACE2 on the host cells and the spike protein present 
on the coronavirus surface. They can also raise the pH of endosomes 
and lysosomes, due to which the fusion method of the virus with 
host cells and resultant replication is forbidden. When HCQ enters 
APCs (antigen-presenting cells), it avoids antigen processing and 
MHC class II-mediated auto antigen exposition to T cells. The further 
initiation of T cells then the appearance of CD154 and further 
cytokines are suppressed. Additionally, it interferes with the contact 
of DNA/RNA with TLRs (toll-like receptors) and the nucleic acid 
sensor cGAS (cyclic GMP-AMP synthase). So, the transcription of 
pro-inflammatory genes can't be stimulated and thus diminish the 
production of pro-inflammatory cytokines. 
As a result, the administration of HCQ not only blocks the invasion 
and repetition of coronavirus but also decreases the opportunity of a 
cytokine storm. Such mechanisms give strong support to the 
hypothesis that HCQ is likely to have the capability to repress the 
CRS (cytokine release syndrome), which is due to over-activation of 
the immune system triggered by SARS-CoV-2 infection, through 
which continuation of the disease from mild to severe might be 
reduced. Still, suspicious clinical examination is instantaneously 
needed to validate this hypothesis [16, 17]. 
 
 
Fig. 2: Potential molecular mechanisms of HCQ [14] 
 
a. HCQ enters and collects in lysosomes sideways the pH gradient. 
Inside lysosomes, it inhibits the degeneration of cargo (such as 
proteins and organelles) derived internally (via the autophagy 
pathway) or externally (via phagocytosis or endocytosis) in 
autolysosomes by accumulative the pH to check the activity of 
lysosomal enzymes. Inhibition of lysosomal activity can stop MHC 
class II-mediated autoantigen presentation. b. HCQ can also bind to 
the minor groove of double-stranded DNA by accumulating in 
endosomes. This drug can suppress Toll-like receptor (TLR) 
signaling by varying the pH of endosomes (involved in TLR 
processing) and/or inhibiting TLR7 and TLR9 from binding their 
ligands (RNA and DNA, respectively). It can also prevent the 
movement of the nucleic acid sensor cyclic GMP-AMP (cGAMP) 
synthase (cGAS) by interfering with its binding to cytosolic DNA. By 
preventing TLR signaling and cGAS-stimulator of interferon genes 
(STING) signaling, HCQ can decrease the production of pro-
inflammatory cytokines, including type I interferons [14]. 
HCQ: side effects in COVID-19 infected patients 
Despite generally safe profiles of CQ and HCQ when used at a low 
dose, both drugs can have important adverse effects, typically 
cardiovascular side effects. Numerous adverse effects of CQ and HCQ 
has been found on cardiac function and conduction, which can be 
fatal. These drugs are proarrhythmic and have an anti-arrhythmic 
property. These drugs have been registered by the American Heart 
Association as the agents, which can cause direct myocardial toxicity 
and aggravate myocardial dysfunction [18]. 
Alexandre et al. surveyed on ‘Off-label’ use and cardiac adverse drug 
reactions of HCQ, azithromycin, lopinavir-ritonavir, and chloroquine 
behaviors in COVID-19 [19]. Based on the experimental properties, 
HCQ (in particular) along with CQ, macrolide antibiotic azithromycin 
(AZI), and anti-HIV protease inhibitor lopinavir (LOPI) have been 
suggested and used for the treatment of COVID-19 [20, 21]. All kinds 
of clinical trials and observational studies have been applied to these 
four drugs worldwide [22-25]. But no strong or considerable data 
has yet been published about their effectiveness in COVID-19, as 
these four drugs have performed poorly so far. On the other hand, 
their safety, related to their tendency to prolong the QT interval of 
the electrocardiogram, remains challenging [26]. These drugs are 
accompanied by a risk of QT prolongation and ‘serious’ cardiac 
arrhythmias imaginably leading to cardiac arrest and sudden death. 
In their survey, out of 120 reports, 103 (85.8%) were linked with the 
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use of HCQ. The reports related to HCQ represented 100% of the 
reports of sudden, unexplained, or aborted deaths and 7% of the 120 
reports of ADRs, 75% of the ventricular arrhythmias. EMA 
(European Medical Agency) and FDA (Food and Drug 
Administration) have defined the use of HCQ in COVID-19 to just 
clinical trials. QTc prolongation and resulting arrhythmogenic risk is 
the most perturbing ADR for these drugs in COVID-19. 
Prescribing HCQ in patients with schizophrenia could also be a 
challenging clinical situation. HCQ is known to cause a spectrum of 
psychiatric adverse effects, including agitation, depression, mania, 
confusion, insomnia, hallucinations, catatonia, and suicidal 
ideation. Hypoglycemia, idiosyncratic hypersensitivity reactions, 
and drug-drug interactions have also been testified with HCQ use, 
and many of these adverse effects can be dose-related [27]. There 
are also several reports of psychosis induced by HCQ in patients 
with no history of psychosis [28]. Patients with schizophrenia can 
have exacerbations of psychotic symptoms during HCQ therapy. 
Considering the current weak evidence base for the use of HCQ in 
the treatment of COVID-19 infection and the significant risk of 
psychotic exacerbation and QTc prolongation, it would be cautious 
to avoid HCQ in patients with schizophrenia [29]. 
Geleris et al. performed an observational study of HCQ in 
Hospitalized Patients with COVID-19. They observed the association 
between HCQ use and death at a huge medical center in New York 
City and related outcomes in patients who received HCQ with those 
in patients who did not, using a multivariable Cox model with 
inverse probability weighting according to the tendency score. From 
their observational study, they found that HCQ-treated patients 
were more severely ill at baseline than those who didn’t receive HCQ 
[30]. So, the study should not be taken to rule out either profit or 
harm of HCQ treatment. However, their decisions do not support the 
use of HCQ at present, outside randomized clinical trials testing its 
effectiveness.  
HCQ can cause heart conduction disorders, with QT interval 
prolongation, bundle branch block, AV block, and torsades de 
pointes [31]. On April 24, 2020, the FDA gives out a safety statement 
in contrast to the use of HCQ for COVID-19 outside of the hospital 
setting or a clinical trial due to the danger of heart rhythm problems 
[32]. Caution must be used when combining them with QT-
prolonging psychotropics. Likewise, hepatotoxic and epileptogenic, 
so caution must be exercised in patients with hepatic disease, or in 
combination with psychotropics that might be hepatotoxic or may 
minor the seizure threshold. Given HCQ's long half-life (40 h), the 
potential for continuous adverse effects and drug-interactions may 
continue for days after the drug has been discontinued [33, 34]. 
Jankelson et al. found evidence of important QT prolongation and 
increased risk of arrhythmia in patients with COVID-19 accepting 
HCQ [35].  
According to D'Cruz et al. [13], Firstly, there is no perfect pre-clinical 
or clinical confirmation yet, for representing the efficiency of HCQ as 
a prophylactic agent for COVID-19. And secondly, drug 
pharmacokinetics in distinct populations such as teenagers (less 
than 12 y), the elderly; and expectant and lactating mothers differ 
significantly from the general population. They are also at a larger 
risk of adverse effects due to HCQ [36-40]. 
Reports collected so far have recommended that several drugs could 
be possible candidates for the treatment of COVID-19, although the 
clinical efficiency of these drugs has not yet been fully assessed. 
Some of these drugs have been summarized in table 1 [41]. 
 
Table 1: Drugs used for the treatment of coronavirus disease (COVID-19) 
Drugs Types Mechanisms of action Past evidence Reference 
Chloroquine 4-aminoquinoline Not clearly known, changes the pH of 
endosomes and believed to prevent viral 
entry, transport, and post-entry events 
Inhibits infection of cells by SARS-CoV-2 in 





4-aminoquinoline Not clearly known, changes the pH of 
endosomes and believed to prevents viral 
entry, transport, and post-entry events 
Prevents infection of cells by SARS-CoV-2 in 
vitro, approved for malaria prophylaxis and 
autoimmune disease (e. g. rheumatic 
diseases). Approved for the treatment of 





Blocks viral cellular entry Effective against SARS-CoV 1 both in vitro 






Blocks viral cellular entry Established anti-HIV medication. No activity 
against coronaviruses or other respiratory 
viruses. No in vitro or clinical data. 
Favipiravir RNA polymerase 
inhibitors 
Inhibits viral RNA-dependent polymerase Broad-spectrum antiviral against influenza, 
arenavirus, bunyavirus, and filovirus 
Remdesivir Adenosine nucleotide 
analogue 
Inhibits viral application Effective against SARS and MERS 
Ribavirin Nucleoside 
analogue 
Inhibits viral RNA synthesis and mRNA 
capping 














IL-6 inhibitor blocks the cytokine storm. No data on SARS or MERS. Tocilizumab 
reduced fever and oxygen requirement in 





Antibody Binds to the virus and block infection 
bind to infected cells and modification in 
the immune system 
Inhibits SARS-CoV-2 entry into cells in vitro 
 
*SARS-severe acute respiratory syndrome, MERS-Middle-East 
respiratory syndrome, HIV-Human Immunodeficiency syndrome, 
T2DM: type 2 diabetes, COVID-19-Coronavirus disease 19. 
Several evidences revealed that HCQ and CQ showed a potential use 
against the COVID-19: 
Singh AK et al. (2020) studied that the small cost of chloroquine and 
HCQ might also be an operational approach to counter COVID-19 
(mostly in patients with diabetes and other co-morbidities in whom 
mortality is high) in resource-constrained and COVID-19 overloaded 
health care systems in middle-and low-income counties including 
India [41]. 
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Liu Jia et al. (2020) revealed that HCQ could powerfully inhibit 
SARS-CoV-2 infection in vitro. In combination with its anti-
inflammatory activity, they predict that the drug has better potential 
to encounter the disease. This chance awaits verification by clinical 
trials. They figure out that HCQ is less lethal than CQ, prolonged and 
overdose usage can still cause poisoning. And the comparatively low 
SI of HCQ needs careful designing and conducting clinical trials to 
achieve efficient and safe control of the SARS-CoV-2 infection [42]. 
CONCLUSION 
Following the major outbreak against COVID-19 infection due to the 
Sars-CoV-2 virus, HCQ and CQ were revealed as a potential drug for 
the treatment of this virus. Unlike antiviral drugs, HCQ has no direct 
effect on SARS-CoV-2. Its use against COVID-19, even as prophylaxis, 
has to be constantly supervised, specifically in individuals with 
previous heart conditions. The low cost of chloroquine and HCQ 
could also be an effective strategy to counter COVID-19. In 
combination with its anti-inflammatory function, it has been 
predicted that the drug has shown a good potential to fight the 
disease. Currently, HCQ combined with azithromycin quickly 
emerged in several countries as one of the most effective treatments 
for patients. However, HCQ needs careful designing and conducting 
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